Does Growth Hormone Drug Slow Alzheimer’s Disease?

Growth hormone is naturally produced in the body and stimulates the release of another hormone called insulin-like growth factor-1 (IGF-1). Studies on mice have suggested that IGF-1 helps reduce beta-amyloid, which is a form of plaque, from the brain. The accumulation of beta-amyloid is a core feature of Alzheimer's disease and is thought to be an important cause of the memory and behavioral symptoms of the disease.

In the study, scientists used the investigational compound MK-677 to boost the blood levels of the hormone. MK-677 stimulates the release of natural growth hormone from the pituitary gland. The growth hormone then stimulates the release of IGF-1 in other parts of the body.

The study involved 416 people who had mild to moderate Alzheimer’s disease who underwent brain scans. Half of the group took MK-677 and the other half took a placebo for one year.

The study found that MK-677 did not slow the symptoms of Alzheimer’s disease even though MK-677 was effective in increasing levels of IGF-1.

“This work suggests that targeting this hormone system may not be an effective approach to slowing the rate of Alzheimer’s disease progression,” says study author J.J. Sevigny, MD, of Merck Research Laboratories in North Wales, PA. “Importantly it challenges the common theory that hormones may attack beta-amyloid plaque in the brain and builds on the body of clinical evidence for Alzheimer's disease as we seek to develop more effective treatments.”

It is estimated that every 70 seconds, someone in the United States develops Alzheimer’s disease. There are only five drugs that are FDA approved to treat the symptoms of the disease.

The study was supported by Merck Research Laboratories.

The American Academy of Neurology, an association of more than 21,000 neurologists and neuroscience professionals, is dedicated to improving patient care through education and research. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as multiple sclerosis, restless legs syndrome, Alzheimer’s disease, narcolepsy, and stroke.

Media Contact

Rachel Seroka American Academy of Neurology

More Information:

http://www.aan.com/press

All latest news from the category: Life Sciences and Chemistry

Articles and reports from the Life Sciences and chemistry area deal with applied and basic research into modern biology, chemistry and human medicine.

Valuable information can be found on a range of life sciences fields including bacteriology, biochemistry, bionics, bioinformatics, biophysics, biotechnology, genetics, geobotany, human biology, marine biology, microbiology, molecular biology, cellular biology, zoology, bioinorganic chemistry, microchemistry and environmental chemistry.

Back to home

Comments (0)

Write a comment

Newest articles

High-energy-density aqueous battery based on halogen multi-electron transfer

Traditional non-aqueous lithium-ion batteries have a high energy density, but their safety is compromised due to the flammable organic electrolytes they utilize. Aqueous batteries use water as the solvent for…

First-ever combined heart pump and pig kidney transplant

…gives new hope to patient with terminal illness. Surgeons at NYU Langone Health performed the first-ever combined mechanical heart pump and gene-edited pig kidney transplant surgery in a 54-year-old woman…

Biophysics: Testing how well biomarkers work

LMU researchers have developed a method to determine how reliably target proteins can be labeled using super-resolution fluorescence microscopy. Modern microscopy techniques make it possible to examine the inner workings…

Partners & Sponsors